Network, Capacity & Capital Strategy
Deciding what capability an organisation needs, where, and whether to build, buy or contract it — including capacity, redundancy, and how much resilience the network carries against losing a site. These decisions set the constraints every other pillar operates inside for decades, and they are made with financial models that rarely carry the regulatory consequences forward.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 20 LINKSA capital decision in a regulated network buys a qualification obligation as well as a building, and the projects that go wrong are usually the ones costed as though only the building were being bought.
06 · QUALITY MATURITY — NETWORK, CAPACITY & CAPITAL STRATEGY, REACTIVE TO ADAPTIVE
Capacity is added when a shortage is imminent. The decision is made on demand forecast and construction cost.
A capital plan exists with a pipeline of projects, appraised on capital and operating cost, with qualification and validation treated as delivery activities rather than as scope.
Appraisal includes the regulatory cost of the choice — qualification, filing, transfer, requalification — so options are compared on what they actually cost to make compliant.
Capacity, flexibility and continuity are traded off explicitly, and the network position of a new asset is decided before the site is.
Capital is deployed against a network strategy that anticipates modality and volume change, so a new facility is useful for products that do not exist yet.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 3 regulatory bodies: EMA, ICH, ISO.
RECORDS & OBJECTIVE EVIDENCE
- The capital plan, with the basis on which projects were prioritised
- Option appraisals including qualification, filing and transfer costs
- Capacity analysis against demand, including the uncertainty in it
- The network rationale for the location and role of new assets
- Post-completion reviews comparing delivered capacity against the case made
COMMON INSPECTION FINDINGS
- Capital appraised on construction cost with qualification treated as a delivery detail
- Capacity decisions made on a single demand scenario with no sensitivity
- A new facility duplicating an existing constraint elsewhere in the network
- No post-completion review, so the same appraisal errors repeat on the next project
- Flexibility designed out to reduce capital, with the cost falling on later changeovers
Capacity and resilience are different numbers
A network can have ample nameplate capacity and no resilience, because the capacity sits in one place. The relevant question is not whether the organisation can make enough, but what happens to supply when the site that makes it stops — and the answer is bounded by qualification lead time, which means the alternative has to exist before the interruption rather than after it.
This is why capacity planning and continuity planning have to be the same conversation. Consolidating production into a modern, efficient site is frequently the right decision and it always increases concentration. Making that trade explicit, with the recovery time for each concentrated product stated alongside the efficiency case, is what turns it from an inherited exposure into a chosen one.
Build, buy or contract allocates capability for a generation
Each route carries a different long-run obligation. Building creates an asset the organisation must qualify, maintain, staff and eventually replace. Buying an existing facility acquires its history — its remediation record, its equipment age, its as-built accuracy — which due diligence frequently underestimates. Contracting transfers the work and retains the accountability, so it requires an internal technical capability that survives the outsourcing.
The comparison is usually made on capital and unit cost over a defined horizon. What is missing is the ongoing regulatory obligation each route creates: qualification burden, inspection exposure, oversight capability, and the cost of exit. Those are estimable at decision time and are almost never in the paper.
Flexibility has to be designed in, and it is not free
A facility built for one product at one scale will be efficient and will constrain everything that follows. Multi-product capability, spare utility capacity, space for an additional line, and services routed for future connection are all cheap at design and expensive to retrofit — but each carries capital cost now against a benefit that may never be needed.
The judgement worth making explicitly is which flexibility is worth buying, based on the portfolio the site is expected to serve rather than on general prudence. Sites built with no flexibility become the constraint on every subsequent product decision; sites built with unlimited flexibility spend capital on optionality that expires unused.
SPEQ interpretation — the quality organisation is a capital decision too
Capital cases size buildings, equipment and utilities. They routinely under-size the quality organisation that will operate them: the laboratory capacity to test what the line produces, the qualified staff to run the shifts, the validation resource to keep the estate in a validated state, and the investigation capacity for the deviations a new operation will generate.
The consequence is a site that can manufacture and cannot release, which appears eighteen months later as laboratory backlog and overdue investigations rather than as a capital shortfall. Sizing the quality organisation in the same paper as the plant is a small addition that prevents the most common form of commissioning disappointment.
FREQUENTLY ASKED
Why is nameplate capacity a poor measure of network resilience?
Because it says nothing about what happens when the site holding it stops. Recovery is bounded by qualification lead time, so the alternative has to exist before the interruption. Consolidation into an efficient site is often correct and always increases concentration — the trade should be explicit, with recovery time stated next to the efficiency case.
What do capital cases usually leave out?
The ongoing regulatory obligation each route creates: qualification burden, inspection exposure, the oversight capability contracting requires, and the cost of exit. All are estimable at decision time and rarely appear in the paper, so they are inherited by functions that were not in the room.
How much design flexibility is worth buying?
As much as the portfolio the site is expected to serve justifies, decided explicitly. Sites built with none become the constraint on every later product decision; sites built with unlimited flexibility spend capital on optionality that expires unused. General prudence is not a basis for either.
What is the most common commissioning disappointment?
A site that can manufacture and cannot release. Capital cases size buildings and equipment and under-size laboratory capacity, qualified staff, validation resource and investigation capacity — so the shortfall appears eighteen months later as backlog and overdue investigations rather than as a capital gap.